Great Portland Estates PLC
Change company Symbol lookup
Select an option...
GPEAF Great Portland Estates PLC
UHAL Amerco
NBRV Nabriva Therapeutics PLC
HRB H & R Block Inc
GM General Motors Co
NDAQ Nasdaq Inc
DYYXF DB Commodity Double Long ETN
KIQ Kelso Technologies Inc
MMM 3M Co
CBOE Cboe Global Markets Inc
Go


Based in United Kingdom
Company profile

Great Portland Estates plc (GPE) is a property investment and development company operating in central London. The Company owns and develops office, retail and residential properties. The Company’s portfolio include tenants from various industry sectors, such as retailers and leisure, technology, media and telecoms, professional services, banking and finance, corporate and government. The Company owns approximately 58 properties in over 43 sites with a total area of approximately 3.1 million square feet. GPE's properties include its Hanover Square Estate, Mount Royal: 508/540 Oxford Street, 30 Broadwick Street, Wells & More: 45 Mortimer Street, Oxford House: 76 Oxford Street, The Piccadilly Buildings, 240 Blackfriars Road, City Place House, City Tower, Minerva House, New City Court: 14/20 St Thomas Street and 122/124 Regent Street.

Price
Delayed
$9.20
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
0

CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS

8:49 pm ET May 22, 2020 (Globe Newswire) Print

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., President and Chief Executive Officer, and Jacob Lalezari, M.D., Chief Science Officer, will host an investment community conference call on Tuesday, May 26, 2020 to provide a comprehensive update on several recent clinical and regulatory developments.

Management will dedicate approximately 30 minutes to address questions from analysts and investors.

Date: Tuesday, May 26, 2020

Time: 1:00 p.m. PT / 4:00 p.m. ET

Dial-In: 877-407-2986 US / 201-378-4916 International

A live audio webcast may also be accessed via CytoDyn's corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software. The webcast can also be accessed via the following link:

https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/38441/indexl.html

A replay of the conference call will be available until June 26, 2020. To access the replay, interested parties may dial 877-660-6853 (US) / 201-612-7415 (international) and enter conference identification number 13702767.

CONTACTS

Investors:

Dave Gentry, CEO

RedChip Companies

Office: 1.800.RED.CHIP (733.2447)

Cell: 407.491.4498

dave@redchip.com

https://ml.globenewswire.com/media/3c50d220-d0d1-4cf0-a0c3-087532ed371c/small/cytodynlogo-png.png

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.